Caitong International Asset Management Co., LTD Candel Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 331 shares of CADL stock, worth $2,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
331
Previous 331
-0.0%
Holding current value
$2,995
Previous $2.87 Million
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CADL
# of Institutions
71Shares Held
10.7MCall Options Held
750KPut Options Held
469K-
Baker Bros. Advisors LP New York, NY2.98MShares$27 Million0.29% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.94MShares$17.6 Million9.1% of portfolio
-
Northpond Ventures, LLC1.94MShares$17.5 Million48.35% of portfolio
-
Braidwell LP Stamford, CT1.6MShares$14.5 Million0.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$12.1 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $261M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...